Retargeting adenoviral vectors to improve gene transfer into tumors

R. T. Hogg, P. Thorpe, R. D. Gerard

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Gene targeting to tumors using adenoviral (Ad) vectors holds great potential for cancer imaging and therapy, but the limited efficacy of current methods used to improve delivery to target tissues and reduce unwanted interactions remain substantial barriers to further development. Progress in characterizing the set of molecular interactions used by Ad vectors to infect particular tissues has aided the development of novel strategies for retargeting vectors to tumor cells. One method is chemical retargeting of adenovirus using bispecific antibodies (bsAbs) against both viral capsid proteins and tumor-specific cell surface molecules. This approach can be combined either with competitive inhibitors designed to reduce viral tropism in undesired tissues, or with traditional therapeutics to increase the expression of surface molecules for improved tumor targeting. Ablating liver cell-specific interactions through mutation of capsid proteins or chemical means are promising strategies for reducing adenovirus-induced liver toxicity. The nature of tumor neovasculature also influences Ad delivery, and the use of vascular disrupting agents (VDAs) such as combretastatin can help elucidate these contributions. In this investigation, we evaluate a variety of these methods for retargeting Ad vectors to tumor cells in vitro and in vivo, and assess the contributions of specific molecular and tissue interactions that affect Ad transgene delivery.

Original languageEnglish (US)
Pages (from-to)275-287
Number of pages13
JournalCancer Gene Therapy
Volume18
Issue number4
DOIs
StatePublished - Apr 2011

Fingerprint

Genes
Neoplasms
Capsid Proteins
Adenoviridae
Viral Tropism
Bispecific Antibodies
Gene Targeting
Liver
Viral Proteins
Transgenes
Cell Communication
Blood Vessels
Mutation
Therapeutics

Keywords

  • adenovirus
  • bavituximab
  • bispecific antibody
  • fiber
  • targeting

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Molecular Biology

Cite this

Retargeting adenoviral vectors to improve gene transfer into tumors. / Hogg, R. T.; Thorpe, P.; Gerard, R. D.

In: Cancer Gene Therapy, Vol. 18, No. 4, 04.2011, p. 275-287.

Research output: Contribution to journalArticle

Hogg, R. T. ; Thorpe, P. ; Gerard, R. D. / Retargeting adenoviral vectors to improve gene transfer into tumors. In: Cancer Gene Therapy. 2011 ; Vol. 18, No. 4. pp. 275-287.
@article{7f0d4f65a674490e8f1837966f33d10c,
title = "Retargeting adenoviral vectors to improve gene transfer into tumors",
abstract = "Gene targeting to tumors using adenoviral (Ad) vectors holds great potential for cancer imaging and therapy, but the limited efficacy of current methods used to improve delivery to target tissues and reduce unwanted interactions remain substantial barriers to further development. Progress in characterizing the set of molecular interactions used by Ad vectors to infect particular tissues has aided the development of novel strategies for retargeting vectors to tumor cells. One method is chemical retargeting of adenovirus using bispecific antibodies (bsAbs) against both viral capsid proteins and tumor-specific cell surface molecules. This approach can be combined either with competitive inhibitors designed to reduce viral tropism in undesired tissues, or with traditional therapeutics to increase the expression of surface molecules for improved tumor targeting. Ablating liver cell-specific interactions through mutation of capsid proteins or chemical means are promising strategies for reducing adenovirus-induced liver toxicity. The nature of tumor neovasculature also influences Ad delivery, and the use of vascular disrupting agents (VDAs) such as combretastatin can help elucidate these contributions. In this investigation, we evaluate a variety of these methods for retargeting Ad vectors to tumor cells in vitro and in vivo, and assess the contributions of specific molecular and tissue interactions that affect Ad transgene delivery.",
keywords = "adenovirus, bavituximab, bispecific antibody, fiber, targeting",
author = "Hogg, {R. T.} and P. Thorpe and Gerard, {R. D.}",
year = "2011",
month = "4",
doi = "10.1038/cgt.2010.78",
language = "English (US)",
volume = "18",
pages = "275--287",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Retargeting adenoviral vectors to improve gene transfer into tumors

AU - Hogg, R. T.

AU - Thorpe, P.

AU - Gerard, R. D.

PY - 2011/4

Y1 - 2011/4

N2 - Gene targeting to tumors using adenoviral (Ad) vectors holds great potential for cancer imaging and therapy, but the limited efficacy of current methods used to improve delivery to target tissues and reduce unwanted interactions remain substantial barriers to further development. Progress in characterizing the set of molecular interactions used by Ad vectors to infect particular tissues has aided the development of novel strategies for retargeting vectors to tumor cells. One method is chemical retargeting of adenovirus using bispecific antibodies (bsAbs) against both viral capsid proteins and tumor-specific cell surface molecules. This approach can be combined either with competitive inhibitors designed to reduce viral tropism in undesired tissues, or with traditional therapeutics to increase the expression of surface molecules for improved tumor targeting. Ablating liver cell-specific interactions through mutation of capsid proteins or chemical means are promising strategies for reducing adenovirus-induced liver toxicity. The nature of tumor neovasculature also influences Ad delivery, and the use of vascular disrupting agents (VDAs) such as combretastatin can help elucidate these contributions. In this investigation, we evaluate a variety of these methods for retargeting Ad vectors to tumor cells in vitro and in vivo, and assess the contributions of specific molecular and tissue interactions that affect Ad transgene delivery.

AB - Gene targeting to tumors using adenoviral (Ad) vectors holds great potential for cancer imaging and therapy, but the limited efficacy of current methods used to improve delivery to target tissues and reduce unwanted interactions remain substantial barriers to further development. Progress in characterizing the set of molecular interactions used by Ad vectors to infect particular tissues has aided the development of novel strategies for retargeting vectors to tumor cells. One method is chemical retargeting of adenovirus using bispecific antibodies (bsAbs) against both viral capsid proteins and tumor-specific cell surface molecules. This approach can be combined either with competitive inhibitors designed to reduce viral tropism in undesired tissues, or with traditional therapeutics to increase the expression of surface molecules for improved tumor targeting. Ablating liver cell-specific interactions through mutation of capsid proteins or chemical means are promising strategies for reducing adenovirus-induced liver toxicity. The nature of tumor neovasculature also influences Ad delivery, and the use of vascular disrupting agents (VDAs) such as combretastatin can help elucidate these contributions. In this investigation, we evaluate a variety of these methods for retargeting Ad vectors to tumor cells in vitro and in vivo, and assess the contributions of specific molecular and tissue interactions that affect Ad transgene delivery.

KW - adenovirus

KW - bavituximab

KW - bispecific antibody

KW - fiber

KW - targeting

UR - http://www.scopus.com/inward/record.url?scp=79952901838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952901838&partnerID=8YFLogxK

U2 - 10.1038/cgt.2010.78

DO - 10.1038/cgt.2010.78

M3 - Article

C2 - 21183946

AN - SCOPUS:79952901838

VL - 18

SP - 275

EP - 287

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 4

ER -